

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B22

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 49/00, G01N 31/00	A1	(11) International Publication Number: WO 99/20314 (43) International Publication Date: 29 April 1999 (29.04.99)
(21) International Application Number: PCT/US98/22218 (22) International Filing Date: 20 October 1998 (20.10.98) (30) Priority Data: 60/062,922 20 October 1997 (20.10.97) US 60/076,985 5 March 1998 (05.03.98) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). (72) Inventors: RICHARD-KORTUM, Rebecca; 6410 Walebridge Lane, Austin, TX 78712 (US). AGRAWAL, Anant; 2104 San Gabriel #214, Austin, TX 78705 (US). PITRIS, Costis; University of Texas at Austin, ENS 610, Dept. of Electrical and Computer Engineering, Austin, TX 78712 (US). UTZINGER, Urs; 5012 Avenue G., Austin, TX 78751 (US). BROOKNER, Carrie; 4707 Forest Home Drive, Missouri City, TX 77459 (US). MITCHELL, Michele, Follen; Apartment 8B, 1111 Hermann Drive, Houston, TX 77004 (US). (74) Agent: LAND, John; Fish & Richardson P.C., Suite 1400, 4225 Executive Drive, La Jolla, CA 92037 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ACETIC ACID AS A SIGNAL ENHANCING CONTRAST AGENT IN FLUORESCENCE SPECTROSCOPY (57) Abstract A method for using acetic acid as a signal enhancing contrast agent during fluorescence spectroscopy of normal and neoplastic tissue, particularly epithelium: In one aspect, the invention includes a method of detecting tissue abnormality in a diagnostic tissue sample in a patient, comprising the steps of obtaining a first fluorescence intensity spectrum from the diagnostic tissue sample; thereafter, applying acetic acid to the diagnostic tissue sample in sufficient concentration to alter the response of such diagnostic tissue sample to electromagnetic radiation for at least an effective period of time; during the effective period of time, obtaining a second fluorescence intensity spectrum from the diagnostic tissue sample; determining a parameter indicative of a change between the first and second fluorescence emission intensity spectra; and analyzing the determined parameter to determine a probability that the diagnostic tissue sample is normal or abnormal.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

ACETIC ACID AS A SIGNAL ENHANCING CONTRAST AGENT IN FLUORESCENCE SPECTROSCOPY

TECHNICAL FIELD

5 The invention relates to methods and apparatus used for optical diagnosis of tissue abnormalities, and more particularly to detection of tissue abnormalities by fluorescence spectroscopy of normal and neoplastic tissue, particularly epithelium.

BACKGROUND

10 Among the many forms of cancer, cervical cancer is the second most common malignancy in women worldwide, exceeded only by breast cancer. In the United States, cervical cancer is the third most common neoplasm of the female genital tract. In 1994, 15,000 new cases of invasive cervical cancer and 55,000 cases of carcinoma *in situ* (CIS) were reported in the U.S. In the same year, an estimated 4,600 deaths occurred in the United States alone from cervical cancer.
15 Recently, the incidence of pre-invasive squamous carcinoma of the cervix has risen dramatically, especially among young women. Women under the age of 35 years account for up to 24.5% of patients with invasive cervical cancer, and the incidence is continuing to increase for women in this age group. It has been estimated that the mortality of cervical cancer may rise by 20% in the next decade unless further improvements are made in detection techniques.

20 Early detection of cervical cancer, or of the pre-cancerous state called squamous intraepithelial lesion (SIL), can reduce the mortality associated with this disease. Currently, a Pap smear is used to screen for CIS and cervical cancer in the general female population. In a Pap smear, a large number of cells, obtained by scraping the cervical epithelium, are smeared onto a slide, which is then fixed and stained for cytologic examination. The Pap smear is unable to
25 achieve a concurrently high sensitivity and high specificity due to both sampling and reading errors. For example, estimates of the sensitivity and specificity of Pap smears screening have ranged from 11-99% and 14-97%, respectively.

- 2 -

Furthermore, reading Pap smears is extremely labor intensive and requires highly trained professionals. A patient with an abnormal Pap smear indicating the presence of SIL is followed up by a diagnostic procedure called colposcopy, which involves colposcopic examination, biopsy and histologic confirmation of the clinical diagnosis. Colposcopy requires extensive training and its accuracy for diagnosis is variable and limited, even in expert hands. Moreover, diagnosis is not immediate. Thus, it would be desirable to provide a way to reduce cervical cancer rates by improving the methods for early detection. It also would be desirable to provide a diagnostic method that could improve the level of specificity and sensitivity, reduce the required skill level of the practitioner interpreting the results, and shorten the time that it takes to arrive at a diagnosis.

In vivo fluorescence spectroscopy is a technique which has the capability to quickly, non-invasively and quantitatively probe the biochemical and morphological changes that occur as tissue becomes neoplastic. The measured spectral information can be correlated to tissue histopathology to develop clinically effective screening and diagnostic techniques. By using automated data analysis techniques, there is the potential for an automated, fast, non-invasive and accurate pre-cancer screening and diagnosis system that can be used by non-experts.

Screening and diagnostic techniques for human tissue, and cervical pre-cancer tissue in particular, based on induced fluorescence spectroscopy have been developed relatively recently; see, for example, the following U.S. Patents and patent applications, the teachings of which are hereby incorporated by reference: 5,699,795 to Richard-Kortums *et al.*, *Optical Probe for the Detection of Cervical Neoplasia Using Fluorescence Spectroscopy and Apparatus Incorporating Same*; 5,697,373 to Richard-Kortums *et al.*, *Optical Method and Apparatus for the Diagnosis of Cervical Precancers Using Raman and Fluorescence Spectroscopies*; 5,623,932 to Ramanujam *et al.*, *Diagnosis of Dysplasia Using Laser Induced Fluorescence*; 5,612,540 to Richard-Kortums *et al.*, *Optical Method for the Detection of Cervical Neoplasias Using Fluorescence Spectroscopy*; 5,562,100 to Kittrell *et al.*, *Method for Laser Induced Fluorescence of Tissue*; 5,697,373 to Richard-Kortums *et al.*, *Optical Method and Apparatus for the Diagnosis of Cervical Precancers Using Raman and Fluorescence Spectroscopies*; 5,612,540 to Richard-Kortums *et al.*, *Optical*

- 3 -

Method for the Detection of Cervical Neoplasias Using Fluorescence Spectroscopy; 5,421,339 to Richard-Kortums *et al.*, *Diagnosis of Dysplasia Using Laser Induced Fluorescence*; 5,419,323 to Kittrell *et al.*, *Method for Laser Induced Fluorescence of Tissue*; 5,345,941 to Rava *et al.*, *Contour Mapping of Spectral Diagnostics*; 5,201,318 to Rava *et al.*, *Contour Mapping of Spectral*
5 *Diagnostics*; SN _____, *Diagnostic Techniques for Cervical Squamous Intraepithelial Lesions in vitro and in vivo Using Fluorescence Spectroscopy*; SN 467,993, *Near-Infrared Raman Spectroscopy for In vitro and in vivo Detection of Cervical Precancers*; SN 693,471, *Method and Apparatus for the characterization of Tissue of Epithelial Lined Viscus*; and SN 672,623, *Spectroscopy Probe for In vivo Measurement of Raman Signals*.

10 A problem with most optical and spectroscopic measurement systems and techniques is obtaining suitable signals indicative of the property to be measured. Contrast agents have been commonly applied to tissue *in vitro* and *in vivo* to enhance the optical return signal of illuminated tissue and thus aid in the extraction of diagnostically useful information from the sample. For example, techniques are commonly used to highlight cellular structures when using light
15 microscopy to examine tissue samples. On a more gross level, sensitive differentiation between normal tissue and neoplasia in various tissue sites has been recently demonstrated through the use of 5-aminolevulinic acid induced protoporphyrin IX fluorescence.

Acetic acid is routinely used during colposcopy, a procedure involving examination of the cervix *in situ* with a low power microscope, to enhance differences between normal and diseased
20 regions of the cervical epithelium. Areas which may develop into cervical cancer undergo a transient whitening (acetowhitening) visible to the naked eye. While the mechanism behind this phenomenon is not yet fully understood, it is commonly agreed that the higher nuclear density present in abnormal epithelium is a significant factor.

The inventors have determined that it would be desirable to provide a technique for the
25 automatic spectroscopic detection of cervical pre-cancer that provides greater sensitivity and selectivity than prior techniques by enhancing the optical return signal in a manner that is indicative of abnormal tissue. The present invention provides such a technique.

- 4 -

SUMMARY

The invention includes use of acetic acid as a signal enhancing contrast agent during fluorescence spectroscopy of normal and neoplastic tissue, particularly epithelium. More particularly, in one aspect, the invention includes a method of detecting tissue abnormality in a diagnostic tissue sample in a patient, comprising the steps of obtaining a first fluorescence intensity spectrum from the diagnostic tissue sample; thereafter, applying acetic acid to the diagnostic tissue sample in sufficient concentration to alter the response of such diagnostic tissue sample to electromagnetic radiation for at least an effective period of time; during the effective period of time, obtaining a second fluorescence intensity spectrum from the diagnostic tissue sample; determining a parameter indicative of a change between the first and second fluorescence emission intensity spectra; and analyzing the determined parameter to determine a probability that the diagnostic tissue sample is normal or abnormal.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1(a) is a graph of fluorescence spectra pre- and post-acetic acid from a pathologically normal site.

FIG. 1(b) is a graph of fluorescence spectra pre- and post-acetic acid from a pathologically abnormal site.

FIG. 2 is a graph showing a mapping of peak emission wavelength shift due to acetic acid from a normal site and an abnormal site.

FIGS. 3(a) and 3(b) are line graphs showing, respectively, the unnormalized and the normalized data of the significance level α for the t -test between categories.

FIGS. 4(a) and 4(b) are bar graphs showing, respectively, the unnormalized ($\alpha=0.07$) and the normalized ($\alpha=0.05$) data of the percentage of wavelengths with differences vs. percentage of patients for each category.

- 5 -

FIGS. 5(a) and 5(b) are line graphs showing, respectively, the unnormalized ($\alpha=0.07$) and the normalized ($\alpha=0.05$) data of significant emission wavelengths vs. percentage of patients for each category.

FIG. 6 is a line graph showing the average difference in intensities (using unnormalized spectra) between categories over all patients.

DETAILED DESCRIPTION

Confirmation of Effect

The invention includes use of acetic acid as a signal enhancing contrast agent during fluorescence spectroscopy of normal and neoplastic tissue, particularly epithelium. To confirm the enhanced optical return signal from use of acetic acid, we measured fluorescence spectra of the cervix *in vivo* from 100 patients referred for colposcopy and treatment due to the presence of cervical precancer. The emission spectra, collected at 337 nm excitation, were acquired using a multi-pixel fiber optic probe designed to collect 31 spatially resolved spectra with 2 mm resolution. The spectra were recorded with an imaging spectrograph onto an imaging array (e.g., a CCD integrated circuit imaging array). Spectra were acquired by placing the probe in each of four quadrants of the cervix both before and after acetic acid (preferably a 3% solution) was applied to the cervix for colposcopy. The patients were then treated by a conventional loop electrosurgical excision procedure to remove the precancerous region of tissue. We identified differences between pre-and post-acetic acid spectra and correlated these differences with the colposcopic impression and pathologic diagnosis.

An example of a spectroscopic system suitable for use in practicing the present invention is described in U.S. Patent No. 5,697,373. This system includes a laser, an optical fiber probe, and an optical multi-channel analyzer utilized to record fluorescence spectra from the intact cervix at colposcopy.

FIG. 1(a) is a graph of fluorescence spectra pre- and post-acetic acid from a pathologically normal site. FIG. 1(b) is a graph of fluorescence spectra pre- and post-acetic acid from a pathologically abnormal site. At the normal site, the addition of acetic acid has little effect on the

- 6 -

peak emission wavelength of the spectrum. However, following addition of acetic acid, the peak of the spectrum from the abnormal site is red-shifted. FIGS. 1(a) and 1(b) illustrate spectra from a single pixel of the multi-pixel probe used to map fluorescence of a 1 cm diameter region of the cervical epithelium.

5 FIG. 2 is a graph showing a mapping of peak emission wavelength shift due to acetic acid from a normal site and an abnormal site. In FIG. 2, the shift in the fluorescence peak emission wavelength post-acetic acid is plotted as a function of pixel location for two placements of the probe, one at a normal site, (a), and one at a site containing a high-grade precancer (b). At the abnormal site (b), the average shift is greater than that of the normal site (a), illustrating that
10 spectral shifts occur consistently throughout normal or abnormal regions of the cervix. Previous studies (Ramanujam, N., *et al.*, "In vivo diagnosis of cervical intraepithelial neoplasia using 337-nm excited laser induced fluorescence", *Proc. Natl. Acad. Sci. USA* 1994, 91:10193-10197) have obtained 337 nm excited fluorescence spectra only post-acetic acid and have shown that the spectra of precancerous tissue exhibit a red shift relative to the spectra of normal tissue. These
15 results are consistent with those presented here, and indicate that acetic acid may play an important role in the ability of 337 nm excited fluorescence to discriminate normal and abnormal cervical epithelium.

The effect of acetic acid as a signal enhancing contrast agent during fluorescence spectroscopy can be shown by statistical analysis. Spectra from a number of patients was obtained
20 as described above, with data taken from four quadrants of the cervix. All data was analyzed per patient. Because of probe placement and pathology methods, all spectra before or after application of acetic acid from each quadrant was classified as normal or abnormal. For categories of spectra were established:

- Normal/Before acetic acid (NB)
- 25 • Abnormal/Before acetic acid (AB)
- Normal/After acetic acid (NA)
- Abnormal/After acetic acid (AA)

- 7 -

A statistical method (*t*-test) was used to compare fluorescence intensities at each emission wavelength between categories:

- NB vs. AB
- NB vs. NA
- 5 • NA vs. AA
- AB vs. AB

The comparisons were made for both normalized (to peak value of 1) and unnormalized spectra.

A significance level (α) for the *t*-test between categories was established as follows: For each patient, the spectra from a single category were divided into to random groups. The mean
10 spectrum for each group was determined. The largest value of α was then determined where the two mean spectra appear to be essentially the same (differences <10% of emission wavelengths) for at least 80% of patients. FIGS. 3(a) and 3(b) are line graphs showing, respectively, the unnormalized and the normalized data of the significance level α for the *t*-test between categories. FIGS. 4(a) and 4(b) are bar graphs showing, respectively, the unnormalized ($\alpha=0.07$) and the
15 normalized ($\alpha=0.05$) data of the percentage of wavelengths with differences vs. percentage of patients for each category.

The amount and spectral dependence of significant differences between categories was then determined. A *t*-test was performed at each emission wavelength to determine if the distributions of intensities for two categories were significantly different. FIGS. 5(a) and 5(b) are
20 line graphs showing, respectively, the unnormalized ($\alpha=0.07$) and the normalized ($\alpha=0.05$) data of significant emission wavelengths vs. percentage of patients for each category.

FIG. 6 is a line graph showing the average difference in intensities (using unnormalized spectra) between categories over all patients. Comparing lines NB-AB and NA-AA, application of acetic acid increases the signal between normal and abnormal tissue at almost all wavelengths compared to data from tissue without acetic acid. Comparing lines NB-NA and AB-AA,
25 application of acetic acid has a greater effect on abnormal tissue than on normal tissue at almost all wavelengths.

- 8 -

Preferred Methods

Having demonstrated that acetic acid can produce measurable differences in optical spectra and images which may be diagnostically useful, the following is the preferred method of embodying this discovery in practice:

- 5 (1) Obtain a first fluorescence emission intensity spectrum from the diagnostic tissue sample, resulting from illuminating the diagnostic tissue sample with excitation electromagnetic radiation. For *in vivo* applications, the tissue is preferably epithelium. For detection of cervical abnormalities, the tissue is preferably epithelium from the cervix. Preferred excitation wavelengths are about 380 nm,
10 337 nm, and 460 nm.
- (2) Thereafter, applying acetic acid to the diagnostic tissue sample in sufficient concentration to alter the response of the diagnostic tissue sample to excitation electromagnetic radiation for at least an effective period of time. Typical
15 concentrations of acetic acid are 3%-6%, but any medically safe concentration that produces the desired alteration in response is suitable.
- (3) During the effective period of time, obtaining a second fluorescence intensity spectrum from the diagnostic tissue sample. Again, preferred excitation wave-
20 lengths are about 380 nm, 337 nm, and 460 nm. In any event, the preferred embodiment utilizes substantially identical excitation wavelengths for both the first and second fluorescence emission intensity spectra.
- (4) A parameter indicative of a change between the first and second fluorescence
25 intensity spectra is then determined. It has been found that application of acetic acid results in a change in measured intensity between the first and second fluorescence emission intensity spectra. Acetic acid causes an overall reduction in detected fluorescence intensity, but with a greater affect on abnormal tissue than on normal tissue. It has also been found that application of acetic acid results in a change in measured red shift between the first and second fluorescence emission intensity spectra, and more particularly a red shift in the peak emission wave-

- 9 -

length. Thus, acetic acid enhances differences in fluorescence intensity and line shape between normal and abnormal tissue. A working hypothesis for the affect of acetic acid on tissue is that acetic acid causes less excitation light (and less emission light) to penetrate "directly" through epithelium due to increased scattering of light. If is further believed that the contribution to emissions by at least certain fluorophores (*e.g.*, NADH, FAD) and absorbers (*e.g.*, hemoglobin) in the stroma beneath the epithelium is diminished.

- (5) Once a desired indicator parameter is determined, the indicator parameter can be analyzed to calculate a probability that the diagnostic tissue sample is normal or abnormal. One method of analysis is simply to compare the indicator parameter to an empirically determined threshold value. If the indicator parameter exceeds the threshold value, an indication can be made of possible tissue abnormality in the diagnostic tissue sample. However, other methods of analysis can be applied that can utilize the fact that application of acetic acid provides an enhanced fluorescence spectra signal between normal and abnormal tissue.

A number of embodiments of the present invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. For example, other apparatus than that described can be used with the inventive method. Accordingly, other embodiments are within the scope of the following claims.

- 10 -

WHAT IS CLAIMED IS:

1. A method of detecting tissue abnormality in a diagnostic tissue sample in a patient, comprising the steps of:
 - 5 (a) obtaining a first fluorescence emission intensity spectrum from the diagnostic tissue sample;
 - (b) thereafter, applying acetic acid to the diagnostic tissue sample in sufficient concentration to alter the response of such diagnostic tissue sample to excitation electromagnetic radiation for at least an effective period of time;
 - 10 (c) during the effective period of time, obtaining a second fluorescence emission intensity spectrum from the diagnostic tissue sample;
 - (d) determining a parameter indicative of a change between the first and second fluorescence emission intensity spectra; and
 - (e) analyzing the determined parameter to determine a probability that the diagnostic tissue
15 sample is normal or abnormal.

- 11 -

2. A method of detecting tissue abnormality in a diagnostic tissue sample in a patient, comprising the steps of:
- (a) illuminating the diagnostic tissue sample with excitation electromagnetic radiation;
 - (b) detecting a first fluorescence emission intensity spectrum from the diagnostic tissue sample resulting from such illuminating;
 - 5 (c) thereafter, exposing the diagnostic tissue sample to acetic acid in sufficient concentration to have the effect of detectably altering the response of such diagnostic tissue sample to excitation electromagnetic radiation for at least an effective period of time;
 - (d) during the effective period of time, further illuminating the diagnostic tissue sample with excitation electromagnetic radiation;
 - 10 (e) detecting a second fluorescence emission intensity spectrum from the diagnostic tissue sample resulting from such further illuminating;
 - (f) determining a parameter indicative of a change between the first and second fluorescence emission intensity spectra; and
 - 15 (g) comparing the determined parameter to a threshold value to indicate tissue abnormality in the diagnostic tissue sample if the determined parameter exceeds the threshold value.

- 12 -

3. The method of claims 1 or 2, wherein the parameter indicative of a change between the first and second fluorescence emission intensity spectra is a parameter indicative of an intensity change.
- 5 4. The method of claims 1 or 2, wherein the parameter indicative of a change between the first and second fluorescence emission intensity spectra is a parameter indicative of hemoglobin absorption.
5. The method of claims 1 or 2, wherein the parameter indicative of a change between the first
10 and second fluorescence emission intensity spectra is a parameter indicative of a red shift.
6. The method of claim 5, wherein the parameter is indicative of a shift in peak emission wavelength.
- 15 7. The method of claims 1 or 2, performed with a cervical tissue sample as the diagnostic tissue sample.
8. The method of claims 1 or 2, wherein the diagnostic tissue sample is *in vivo*.
- 20 9. The method of claim 1, wherein the step of analyzing the determined parameter to determine a probability that the diagnostic tissue sample is normal or abnormal includes the step of comparing the determined parameter to a threshold value to indicate tissue abnormality in the diagnostic tissue sample if the determined parameter exceeds the threshold value.

- 13 -

10. The method of claim 2, wherein the electromagnetic radiation in steps (a) and (d) are essentially identical wavelengths.
11. The method of claim 2, wherein the electromagnetic radiation used in steps (a) and (d)
5 has a wavelength of about 380 nm.
12. The method of claim 2, wherein the electromagnetic radiation used in steps (a) and (d) has a wavelength of about 337 nm.
- 10 13. The method of claim 2, wherein the electromagnetic radiation used in steps (a) and (d) has a wavelength of about 460 nm.

1/5




FIG. 1(a)




FIG. 1(b)




FIG. 2

2/5

Fig. 3(b)





Fig. 3(a)



3/5

Fig. 4(b)





Fig. 4(a)



4/5

Fig. 5(a)




Fig. 5(b)





Fig. 6



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/22218

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 49/00; G01N 31/00

US CL :424/9.6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/91.11, 1.37, 1.65, 1.81, 9.1, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8; 562/607, 1, 400; 600/473; 128/664

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, MEDLINE, USPATFULL, EMBASE, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, E	US 5,842,995 A (MAHADEVAN-JANSEN et al.) 01 December 1998, see entire document, especially, column 15, lines 25-42.	1-13
Y, P	US 5,697,373 A (RICHARDS-KORTUM et al.) 16 December 1997, see entire document, especially, abstract, columns 1-3, lines 50-68, 1-68, and 1-48, respectively.	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents.	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 DECEMBER 1998

Date of mailing of the international search report

01 FEB 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer:

D. Jones

Telephone No. (703) 308-1235